Last checked at 23 Aug 2023 07:00
23 August 2023
Destiny Pharma plc("Destiny Pharma" or "the Company")
Notice of Interim Results
Brighton, United Kingdom - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and treat life threatening infections, will announce its interim results for the period ended 30 June 2023 on Wednesday 20 September 2023.
On 20 September 2023, the Company will host a briefing for analysts at 8.30am BST, followed by a presentation to all existing and potential shareholders at 11.00am BST held via the Investor Meet Company platform. Further details for the analyst briefing will be shared by invitation in due course.
The analyst briefing and investor presentation will be led by Chris Tovey, the incoming Chief Executive Officer set to join the Company on Friday 1 September 2023, and Shaun Claydon, Chief Financial Officer.
Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00 am BST the day before the meeting, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma plc via: https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited.
- END -
For further information, please contact:
Destiny Pharma plc Debra Barker, Interim CEOShaun Claydon, CFO+44 (0)1273 704 440 pressoffice@destinypharma.com
Powerscourt Group Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward+44 (0) 20 7250 1446
Destiny@powerscourt-group.com
finnCap Ltd (Nominated Advisor and Joint Broker) Geoff Nash / George Dollemore, Corporate FinanceAlice Lane / Nigel Birks / Harriet Ward, ECM+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.
For further information on the company, please visit www.destinypharma.com